news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

China News Service, July 23 (Lin Wansi) "In China, high-value vaccine varieties are in use and play a role, but most of them still rely on imports. Rapidly upgrading and developing innovative vaccines that meet China's public health needs has always been the common goal of disease control, drug supervision departments and companies." Recently, CanSino Biologics Chief Scientific Officer Zhu Tao said in an interview with China News Service.

Zhu Tao has been engaged in vaccine research, development and application for 20 years. He pointed out that the vaccine industry has important economic value. For example, the global market for cervical cancer vaccines exceeds 8 billion US dollars, and pneumonia vaccines also exceed 6 billion US dollars.

When talking about developing the "new quality productivity" of the vaccine industry, Zhu Tao believes that more investment should be made in vaccine innovation, a sound innovation incentive mechanism should be established, and a linkage and cooperation mechanism among disease control, drug supervision and industry associations should be established to accelerate the provision of vaccines urgently needed for public health in China and the world.

He said that in the field of vaccine production, some manufacturers are limited to producing a single type of vaccine, resulting in the dispersion and waste of resources.

"The research and development and production of vaccines is a process that is highly dependent on the investment of funds, technology and talents. However, if each manufacturer only focuses on a specific variety, the resources invested will not be fully optimized, which will undoubtedly have an adverse impact on the sustainable and healthy development of the entire vaccine industry." Zhu Tao said that as a special product directly related to the safety of people's lives, the production process of vaccines must strictly follow national laws, regulations and relevant standards. With the development of China's vaccine industry and the increase in vaccine companies, the regulatory authorities are also facing unprecedented challenges in the face of a large number of vaccine manufacturers.

Zhu Tao also pays close attention to the optimization of the vaccine industry. He suggested that, first, the government should strengthen the planning and guidance of the vaccine industry, establish and improve relevant systems, optimize resource allocation through pilot commissioned production and other forms, encourage cooperation between enterprises, activate production capacity, and improve the concentration and scale benefits of vaccine production.

Second, regulatory authorities should increase supervision of the vaccine production process to ensure that every manufacturer strictly abides by relevant laws and standards, increase penalties for violations, and create an effective deterrent.

The third is to strengthen vaccine economics research and post-market evaluation of vaccines, conduct a comprehensive assessment and analysis of the vaccine's economic value, economic attributes, supply and demand characteristics, price, market, funding, etc., and conduct follow-up evaluation after the vaccine is launched. This will play a positive role in solving the dispersion and waste of resources, eliminating inefficient and difficult-to-regulate companies, and providing data support for the country to formulate immunization strategies.

(For more reporting clues, please contact the author of this article, Lin Wansi: [email protected]) (China News Service APP)

　　(The views in this article are for reference only and do not constitute investment advice. Investment is risky and you should be cautious when entering the market.)

　　All rights reserved by China Business Network. No organization or individual may reprint, excerpt or use in other ways without written authorization.

Editors: Chang Tao and Luo Kun